The use of targeted therapies, such as trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2 positive (HER2+) tumors that constitute approximately 20% of all breast cancers, has been tremendously successful [3, 4]. This evidence concerns the gene ERBB2 and breast cancer.